文献速递妇科生殖医学

妇科癌症患者卵巢组织冷冻保存与移植的效用及结局:系统综述与Meta分析

Utility and Outcomes of Ovarian Tissue Cryopreservation and Transplantation for Gynecologic Cancers: A Systematic Review and Meta-analysis.
PubMed 文献 · Obstet Gynecol · 2024-08-22

该系统综述与Meta分析共纳入23项研究,评估妇科癌症患者卵巢组织冷冻保存与自体移植的效用、成功率及安全性。结果显示妇科癌症分别占冷冻保存与自体移植指征的7.5%和9.6%,自体移植后78.1%的患者卵巢内分泌功能恢复,中位移植物存活32个月,未见移植部位复发。作者认为该技术是保留卵巢功能的可行选择,但应用不足,需进一步研究长期结局。

要点

  • 妇科癌症占卵巢组织冷冻保存指征的7.5%,占自体移植指征的9.6%。
  • 妇科癌症患者自体移植后卵巢内分泌功能恢复比例为78.1%,中位移植物存活32个月。
  • 妇科癌症患者自体移植后未见移植部位复发,但作者指出该技术应用不足且需进一步研究长期结局。

核心结论

  • 作者认为卵巢组织冷冻保存与自体移植是妇科癌症女性保留卵巢功能的可行选择,但卵巢组织冷冻保存应用不足,需进一步研究以确定自体移植的长期结局。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE、ClinicalTrials.gov和Cochrane Library数据库,检索时间自建库至2024年1月23日,共纳入23项研究。
  • 由两名评价者独立进行研究筛选、数据提取和偏倚风险评估,随后共同复核结果。

主要发现

  • 接受卵巢组织冷冻保存的女性中7.5%为妇科癌症,接受自体移植的女性中9.6%为妇科癌症。
  • 血液系统恶性肿瘤和乳腺癌约占这些操作全部指征的66.0%。
  • 妇科癌症患者自体冷冻卵巢组织移植的返回率为6.0%,与其他指征相比无统计学差异。
  • 接受卵巢刺激的妇科癌症女性中27.3%至少有一名子女。
  • 自体移植后78.1%的女性卵巢内分泌功能恢复,中位移植物存活时间为32个月,妇科癌症女性自体移植后未见移植部位复发。

关键数值与推荐

  • 妇科癌症占卵巢组织冷冻保存指征的7.5%,占自体移植指征的9.6%。
  • 妇科癌症患者自体冷冻卵巢组织移植返回率为6.0%,与其他指征无统计学差异。
  • 接受卵巢刺激的妇科癌症女性中27.3%至少有一名子女。
  • 自体移植后78.1%的女性卵巢内分泌功能恢复。
  • 中位移植物存活时间为32个月,妇科癌症女性自体移植后未见移植部位复发。

临床怎么用

  • 作者认为卵巢组织冷冻保存与自体移植是妇科癌症女性保留卵巢功能的可行选择。
  • 作者指出卵巢组织冷冻保存应用不足,需进一步研究以确定自体移植的长期结局。

局限性

  • 作者指出卵巢组织冷冻保存应用不足。
  • 作者指出需进一步研究以确定自体移植的长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the utility, success, and safety of ovarian tissue cryopreservation and autologous cryopreserved ovarian tissue transplantation for fertility preservation in patients with gynecologic cancers. DATA SOURCES: A comprehensive search was performed of the MEDLINE, EMBASE, ClinicalTrials.gov , and Cochrane Library databases to identify relevant studies on the utility and outcomes of ovarian tissue cryopreservation and autologous cryopreserved ovarian tissue transplantation for gynecologic cancers from inception until January 23, 2024. METHODS OF STUDY SELECTION: Two reviewers independently performed the study selection, data extraction, and risk-of-bias assessment, and the results were then reviewed together. Twenty-three studies were included in the current systematic review. TABULATION, INTEGRATION, AND RESULTS: The resultant data were meta-analyzed to produce a pooled-effect estimate of the utility of ovarian tissue cryopreservation and autologous transplantation in gynecologic cancers as a proportion of all indications. We found that 7.5% and 9.6% of women undergoing ovarian tissue cryopreservation and autologous transplantation, respectively, had gynecologic cancers. In comparison, hematologic malignancies and breast cancer accounted for approximately 66.0% of all indications for these procedures. The return rate for autologous cryopreserved ovarian tissue transplantation in gynecologic cancers (6.0%) was not statistically different from those for other indications. Among women with gynecologic cancer who underwent ovarian stimulation, 27.3% had at least one child, and the ovarian endocrine function was restored in 78.1% of the women after autologous transplantation. The median graft longevity was 32 months, and no graft-site recurrence was reported after autologous transplantation in women with gynecologic cancer. CONCLUSION: Our results suggest that ovarian tissue cryopreservation and autologous transplantation are feasible options for preserving ovarian function in women with gynecologic cancers, although ovarian tissue cryopreservation is underutilized, and further studies are needed to determine the longer-term outcomes of autologous transplantation. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42024498522.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Erden M, Gayete-Lafuente S, Vural NA, et al. Utility and Outcomes of Ovarian Tissue Cryopreservation and Transplantation for Gynecologic Cancers: A Systematic Review and Meta-analysis. Obstet Gynecol. 2024. PMID: 39173181. doi:10.1097/AOG.0000000000005708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。